NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
NRx Pharmaceuticals Receives FDA Approval Of Its Abbreviated New Drug Application For Preservative-Free Ketamine
NRx Pharmaceuticals (NRXP) Stock Jumps Over 26% After Hours: What's Behind the Surge?
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
NRx Pharmaceuticals Completes Three Process Validation Lots Of Preservative Free Ketamine Produced Under Commercial Conditions In Anticipation Of Nov. 10 Generic Drug User Fee Amendments Goal Date
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
NRx Pharmaceuticals Announces FDA Receipt Of DISCIPLINE REVIEW LETTER For Changes To Submitted Label For Preservative-Free Ketamine Product Ahead Of Nov. 10
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
NRx Pharma’s NRx Defense Systems Announces Award Of Initial $11M Contract Issued By Defense Advanced Research Projects Agency
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
FDA Reclassifies NRx Pharmaceuticals' Ketamine ANDA Amendment To Minor, Setting New Goal Date For November 10, 2026
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.